Compare Costco Wholesale Corporation (COST) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Moderna, Inc. — how do they compare? Costco Wholesale Corporation trades at $950.89 (market cap $418.79B), while Moderna, Inc. trades at $64.04 (market cap $24.18B). The key difference: Costco Wholesale Corporation is far larger — about 17.3× Moderna, Inc.'s market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| COST | MRNA | |
|---|---|---|
Market Cap | $418.79B | $24.18B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $81.80 |
52-Week Low | $849.63 | $22.36 |
Enterprise Value | $406.93B | $20.33B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $948.1, down 0.49% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $275.24B in 2025 and net income of $8.10B, though it missed Q1 2026 EPS estimates. Recent news highlights March sales up 11.3% year-over-year and institutional buying activity, while the stock remains near its 52-week high of $1,067.08.
Outlook is supported by robust membership fee growth and expansion, but high valuation ratios like a P/E of 47.5 pose risks. Analyst consensus is bullish with a $1,120 price target, though competitive pressures and economic sensitivity could challenge margins. The stock offers long-term growth potential if valuation aligns with earnings momentum.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
